See more : Intercontinental Exchange, Inc. (ICE) Income Statement Analysis – Financial Results
Complete financial analysis of Bicycle Therapeutics plc (BCYC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Bicycle Therapeutics plc, a leading company in the Biotechnology industry within the Healthcare sector.
- Sigma Labs, Inc. (SGLB) Income Statement Analysis – Financial Results
- PT Dayamitra Telekomunikasi Tbk. (MTEL.JK) Income Statement Analysis – Financial Results
- AirBoss of America Corp. (BOS.TO) Income Statement Analysis – Financial Results
- Shreyas Shipping and Logistics Limited (SHREYAS.BO) Income Statement Analysis – Financial Results
- ALSP Orchid Acquisition Corporation I (ALORU) Income Statement Analysis – Financial Results
Bicycle Therapeutics plc (BCYC)
About Bicycle Therapeutics plc
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/II clinical trial targeting EphA2; and BT8009, which is in Phase I/II clinical trial targeting Nectin-4. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase II clinical trials for the treatment of diabetic macular edema; BT7480, a Bicycle tumor-targeted immune cell agonist (TICA) targeting Nectin-4 and agonizing; BT7455, an EphA2/CD137 Bicycle TICA, which is in preclinical studies; and BT1718, a BTC that target tumors, that is in Phase I/IIa clinical trial that express Membrane Type 1 matrix metalloproteinase. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. It has a clinical trial and license agreement with the Cancer Research Technology Limited and Cancer Research UK; research collaboration agreements with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund; and discovery collaboration and license agreement with Genentech for the discovery and development of Bicycle peptides for multiple immuno-oncology targets. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 26.98M | 14.46M | 11.70M | 10.39M | 13.80M | 7.14M | 2.06M | 0.00 |
| Cost of Revenue | 6.47M | 3.69M | 44.88M | 33.15M | 25.54M | 20.76M | 11.87M | 269.29K |
| Gross Profit | 20.51M | 10.78M | -33.18M | -22.76M | -11.74M | -13.63M | -9.81M | -269.29K |
| Gross Profit Ratio | 76.03% | 74.51% | -283.69% | -219.05% | -85.06% | -190.93% | -476.02% | 0.00% |
| Research & Development | 156.50M | 81.61M | 44.88M | 33.15M | 25.54M | 20.76M | 11.87M | 9.77M |
| General & Administrative | 59.83M | 49.51M | 32.44M | 29.20M | 14.56M | 8.12M | 6.41M | 3.78M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -325.11K |
| SG&A | 59.83M | 49.51M | 32.44M | 29.20M | 14.56M | 8.12M | 6.41M | 3.45M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | -5.38M | -665.00K | -119.00K | 0.00 |
| Operating Expenses | 216.92M | 131.12M | 77.32M | 62.35M | 40.10M | 28.88M | 18.27M | 13.22M |
| Cost & Expenses | 216.92M | 131.12M | 77.32M | 62.35M | 40.10M | 28.88M | 18.27M | 13.49M |
| Interest Income | 14.00M | 5.76M | 120.00K | 683.00K | 814.00K | 169.00K | 50.00K | 8.00K |
| Interest Expense | 3.26M | 3.34M | 2.98M | 457.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 6.55M | 3.69M | 1.41M | 1.29M | 963.97K | 710.80K | 335.56K | 269.29K |
| EBITDA | -183.40M | -112.96M | -64.08M | -50.39M | -30.03M | -21.49M | -15.88M | -13.26M |
| EBITDA Ratio | -679.86% | -766.76% | -559.96% | -493.52% | -190.56% | -294.76% | -770.92% | 0.00% |
| Operating Income | -189.95M | -116.65M | -65.62M | -51.96M | -26.30M | -21.75M | -16.21M | -13.49M |
| Operating Income Ratio | -704.13% | -806.56% | -560.98% | -500.10% | -190.56% | -304.74% | -787.04% | 0.00% |
| Total Other Income/Expenses | 10.74M | 2.41M | -2.86M | 226.00K | -4.56M | -496.00K | -69.00K | -37.90K |
| Income Before Tax | -179.21M | -114.24M | -68.48M | -51.73M | -30.86M | -22.24M | -16.28M | -13.53M |
| Income Before Tax Ratio | -664.32% | -789.88% | -585.47% | -497.92% | -223.62% | -311.69% | -790.39% | 0.00% |
| Income Tax Expense | 1.46M | -1.52M | -1.66M | -724.00K | -254.00K | -396.00K | -23.00K | -20.94K |
| Net Income | -180.66M | -112.72M | -66.82M | -51.01M | -30.61M | -21.85M | -16.26M | -13.51M |
| Net Income Ratio | -669.72% | -779.35% | -571.25% | -490.95% | -221.78% | -306.14% | -789.27% | 0.00% |
| EPS | -5.08 | -3.80 | -2.67 | -2.66 | -2.77 | -1.64 | -1.22 | -0.76 |
| EPS Diluted | -5.08 | -3.80 | -2.67 | -2.66 | -2.77 | -1.64 | -1.22 | -0.76 |
| Weighted Avg Shares Out | 35.59M | 29.66M | 25.06M | 19.15M | 11.05M | 13.29M | 13.29M | 17.70M |
| Weighted Avg Shares Out (Dil) | 35.59M | 29.66M | 25.06M | 19.15M | 11.05M | 13.29M | 13.29M | 17.70M |
Bicycle Therapeutics to Present at the AACR Annual Meeting 2024
Bicycle Therapeutics to Participate in Upcoming Investor Conferences
Bicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results
Bicycle Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Bicycle Therapeutics Provides Data Updates for Three Clinical Programs and Strategy Overview at First R&D Day
Bicycle Therapeutics to Host R&D Day on December 14
Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2023 Financial Results and Announces Upcoming R&D Day
Bicycle Therapeutics to Participate in Upcoming Investor Conferences
Bicycle Therapeutics Selected to Participate in FDA Program to Expedite Commercial Manufacturing Readiness of BT8009 for Metastatic Bladder Cancer
Macomics Announces the Appointment of Kevin Lee as Independent Non-Executive Director
Source: https://incomestatements.info
Category: Stock Reports